Phenotypes associated with this allele

• Allele Symbol: Tg(ML5sHEL)5Ccg
• Allele Name: transgene insertion 5, Christopher C Goodnow
• Allele ID: MGI:2384160
• Summary: 13 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Cd19^tm1(cre)Cgn/Cd19^+ Pten^tm1Hwu/Pten^tm1Hwu Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6	MGI:5007685
cx2	Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0	C57BL/6-Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg	MGI:3793461
cx3	Cd19^tm1(cre)Cgn/Cd19^tm1(cre)Cgn Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0	involves: 129P2/OlaHsd * C57BL/6	MGI:5007684
cx4	Prkcd^tm1Qxu/Prkcd^tm1Qxu Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0	involves: 129P2/OlaHsd * C57BL/6	MGI:3841845
cx5	Card19^tm1Rwen/Card19^tm1Rwen Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0	involves: 129P2/OlaHsd * C57BL/6 * C57BL/6JSfd	MGI:7514963
cx6	Endou^tm1Tft/Endou^tm1Tft Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0	involves: 129S/SvEv * C57BL/6 * C57BL/6JSfd	MGI:5582909
cx7	Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0	involves: C57BL/6	MGI:3799370
cx8	Tg(ML5sHEL)5Ccg/0 Tg(TcrHEL3A9)1Mmd/0	involves: C57BL/6 * C57BL/10 * C57BR/cd	MGI:3799690
cx9	Igh^tm1Rbr/Igh^+ Tg(IgkHyHEL10)1Rbr/0 Tg(ML5sHEL)5Ccg/0	involves: C57BL/6 * C57BL/6JSfd	MGI:3800476
cx10	Tg(ML5sHEL)5Ccg/0 Tg(TcrHEL3A9)1Mmd/0 Tg(TLK2mHEL)2Ccg/0	involves: C57BL/6JSfd * C57BL/10 * C57BR/cd	MGI:3799695
cx11	Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0	NOD.B6-Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg/Dvs	MGI:3793444
tg12	Tg(ML5sHEL)5Ccg/0	C57BL/6-Tg(ML5sHEL)5Ccg	MGI:3800597
tg13	Tg(ML5sHEL)5Ccg/0	involves: C57BL/6JSfd * CBA	MGI:3800598

Genotype
MGI:5007685

cn1

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Pten^tm1Hwu/Pten^tm1Hwu; Tg(IghelMD4)4Ccg/0; Tg(ML5sHEL)5Ccg/0
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

abnormal peripheral B cell anergy ( J:155314 )

• failed tolerance induction resulting in abundant autoantibody production, indicating that B cells are prevented from acquiring an anergic state

• B cells have about 10 fold lower bound HEL than in mutants with intact Pten, suggesting that receptor occupancy is reduced on mutant autoreactive B cells and that less HEL is available in adults for inducing and sustaining anergy

• increasing the concentration of free self-antigen confers an anergic phenotype on mutant B cells, but they remain long-lived

Genotype
MGI:3793461

cx2

• Allelic Composition: Tg(IghelMD4)4Ccg/0; Tg(ML5sHEL)5Ccg/0
• Genetic Background: C57BL/6-Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg

immune system

abnormal immature B cell morphology ( J:109923 )

• expression of IgM is 2- to 5- fold lower than on immature B cells found in mice carrying just the Tg(IghelMD4)4Ccg

• there are reduced numbers of immature B cells bearing transgenic IgM in the bone marrow

abnormal pro-B cell morphology ( J:109923 )

• there are reduced numbers of pro-B cells bearing transgenic IgM in the bone marrow

decreased B cell number ( J:89156 )

• almost all of the B cells express the transgenic antibody

• the number of B cells expressing the transgenic antibody is 30% less than found in singly transgenic mice carrying just the antibody transgene

• this demonstrates that partial deletion occurs of B cells that recognize soluble self antigen

abnormal mature B cell morphology ( J:109923 )

• there is an increased percentage of mature B cells in the bone marrow

abnormal germinal center B cell morphology ( J:109923 )

• B cells expressing the transgenic Ig are absent from the germinal center of the spleen and lymph nodes

abnormal plasma cell morphology ( J:109923 )

• plasma cells producing transgenic Ig are found rarely in these mice

abnormal spleen B cell follicle morphology ( J:109923 )

• splenic B cells bearing transgenic Ig are restricted to the follicular mantle zones

decreased IgM level ( J:78308 , J:89156 )

• very little IgM is detectable in the sera despite the presence of soluble antigen for the transgenic antibody (J:89156)

abnormal B cell anergy ( J:78308 , J:89156 )

• B cells expressing the transgenic antibody are anergic as determined by the lack of HEL specific antibody found in the sera (J:89156)

• anergy occurs both centrally (i.e. in the bone marrow) and in the periphery (J:89156)

• this anergy can be reversed by stimulating B cells in vitro (J:89156)

abnormal central B cell anergy ( J:109923 )

• immature B cells in the bone marrow lack reactivity when transferred to irradiated host mice that are immunized with a HEL antigen

hematopoietic system

abnormal immature B cell morphology ( J:109923 )

• there are reduced numbers of immature B cells bearing transgenic IgM in the bone marrow

• expression of IgM is 2- to 5- fold lower than on immature B cells found in mice carrying just the Tg(IghelMD4)4Ccg

abnormal pro-B cell morphology ( J:109923 )

• there are reduced numbers of pro-B cells bearing transgenic IgM in the bone marrow

decreased B cell number ( J:89156 )

• almost all of the B cells express the transgenic antibody

• the number of B cells expressing the transgenic antibody is 30% less than found in singly transgenic mice carrying just the antibody transgene

• this demonstrates that partial deletion occurs of B cells that recognize soluble self antigen

abnormal mature B cell morphology ( J:109923 )

• there is an increased percentage of mature B cells in the bone marrow

abnormal germinal center B cell morphology ( J:109923 )

• B cells expressing the transgenic Ig are absent from the germinal center of the spleen and lymph nodes

abnormal plasma cell morphology ( J:109923 )

• plasma cells producing transgenic Ig are found rarely in these mice

abnormal spleen B cell follicle morphology ( J:109923 )

• splenic B cells bearing transgenic Ig are restricted to the follicular mantle zones

decreased IgM level ( J:78308 , J:89156 )

• very little IgM is detectable in the sera despite the presence of soluble antigen for the transgenic antibody (J:89156)

Genotype
MGI:5007684

cx3

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19^tm1(cre)Cgn; Tg(IghelMD4)4Ccg/0; Tg(ML5sHEL)5Ccg/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

hematopoietic system

decreased B cell number ( J:155314 )

• low splenic and lymph node B cell numbers

immune system

immune system phenotype ( J:155314 )

N • tolerance mechanisms to prevent autoantibody production are intact and B cells are able to selectively downregulate IgM

decreased B cell number ( J:155314 )

• low splenic and lymph node B cell numbers

Genotype
MGI:3841845

cx4

• Allelic Composition: Prkcd^tm1Qxu/Prkcd^tm1Qxu; Tg(IghelMD4)4Ccg/0; Tg(ML5sHEL)5Ccg/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

immune system phenotype ( J:76134 )

N • B cell activation in vitro and in vivo are normal

decreased B cell number ( J:76134 )

• peripheral B cells are reduced compared to in Prkcd^tm1Qxu/Prkcd^tm1Qxu Tg(IghelMD4)4Ccg mice

abnormal spleen primary B follicle morphology ( J:76134 )

• the number of B follicles is increased compared to in Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg mice

increased spleen germinal center number ( J:76134 )

abnormal B cell physiology ( J:76134 )

• surface levels of IgMa are decreased 2-fold compared to in Prkcd^tm1Qxu/Prkcd^tm1Qxu Tg(IghelMD4)4Ccg mice

abnormal B cell proliferation ( J:76134 )

• B cells proliferate vigorously in response to HEL unlike Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg mice

abnormal self tolerance ( J:76134 )

• B cells switch to an autoreactive phenotype and fail to induce tolerance

• B cells proliferate vigorously in response to HEL unlike Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg mice

autoimmune response ( J:76134 )

• mice exhibit an 80-fold increase in HEL-specific antibodies compared to in Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg mice

hematopoietic system

decreased B cell number ( J:76134 )

• peripheral B cells are reduced compared to in Prkcd^tm1Qxu/Prkcd^tm1Qxu Tg(IghelMD4)4Ccg mice

abnormal spleen primary B follicle morphology ( J:76134 )

• the number of B follicles is increased compared to in Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg mice

increased spleen germinal center number ( J:76134 )

abnormal B cell physiology ( J:76134 )

• surface levels of IgMa are decreased 2-fold compared to in Prkcd^tm1Qxu/Prkcd^tm1Qxu Tg(IghelMD4)4Ccg mice

abnormal B cell proliferation ( J:76134 )

• B cells proliferate vigorously in response to HEL unlike Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg mice

cellular

abnormal B cell proliferation ( J:76134 )

• B cells proliferate vigorously in response to HEL unlike Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg mice

Genotype
MGI:7514963

cx5

• Allelic Composition: Card19^tm1Rwen/Card19^tm1Rwen; Tg(IghelMD4)4Ccg/0; Tg(ML5sHEL)5Ccg/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * C57BL/6JSfd

immune system

increased B cell apoptosis ( J:336763 )

• increased apoptosis of B cells in response to self-antigen HEL or anti-IgM stimulation

decreased B cell proliferation ( J:336763 )

• self-reactive B-cells are less proliferative in response to BCR engagement

decreased B cell number ( J:336763 )

• decrease in the B cell population in the spleen indicating enhanced B cell tolerance

increased B cell number ( J:336763 )

• increase in the frequency of gamma L chain positive splenic B cells compared to transgenic mice wild-type for Card19

hematopoietic system

increased B cell apoptosis ( J:336763 )

• increased apoptosis of B cells in response to self-antigen HEL or anti-IgM stimulation

decreased B cell proliferation ( J:336763 )

• self-reactive B-cells are less proliferative in response to BCR engagement

decreased B cell number ( J:336763 )

• decrease in the B cell population in the spleen indicating enhanced B cell tolerance

increased B cell number ( J:336763 )

• increase in the frequency of gamma L chain positive splenic B cells compared to transgenic mice wild-type for Card19

cellular

increased B cell apoptosis ( J:336763 )

• increased apoptosis of B cells in response to self-antigen HEL or anti-IgM stimulation

decreased B cell proliferation ( J:336763 )

• self-reactive B-cells are less proliferative in response to BCR engagement

Genotype
MGI:5582909

cx6

• Allelic Composition: Endou^tm1Tft/Endou^tm1Tft; Tg(IghelMD4)4Ccg/0; Tg(ML5sHEL)5Ccg/0
• Genetic Background: involves: 129S/SvEv * C57BL/6 * C57BL/6JSfd

immune system

immune system phenotype ( J:208364 )

N • B cell phenotypes observed in Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg mice are normalized

decreased activation-induced B cell apoptosis ( J:208364 )

• absent in high responder mice

increased autoantibody level ( J:208364 )

• increased anti-HEL auto-antibody production compared with control mice

cellular

decreased activation-induced B cell apoptosis ( J:208364 )

• absent in high responder mice

hematopoietic system

decreased activation-induced B cell apoptosis ( J:208364 )

• absent in high responder mice

Genotype
MGI:3799370

cx7

• Allelic Composition: Tg(IghelMD4)4Ccg/0; Tg(ML5sHEL)5Ccg/0
• Genetic Background: involves: C57BL/6

immune system

decreased B cell number ( J:76134 )

• peripheral B cells are reduced compared to in Tg(IghelMD4)4Ccg mice

decreased marginal zone B cell number ( J:132538 )

• very few B cells in the spleen have surface markers indicative of the marginal zone phenotype

abnormal spleen primary B follicle morphology ( J:76134 )

• the number of B follicles is decreased compared to in Tg(IghelMD4)4Ccg mice

abnormal B cell physiology ( J:76134 )

• surface levels of IgMa are decreased 7- to 11-fold compared to in Tg(IghelMD4)4Ccg mice

abnormal B cell anergy ( J:73608 , J:132538 )

• B cells from these mice are unable to activate HEL-specific CD4 T cells from Tg(TcrHEL3A9)1Mmd mice when co-cultured together in the presence of HEL protein (J:73608)

• B cells are anergic when stimulated with HEL antigen as determined by reduced antibody production, no upregulation of activation markers CD69 and CD86, and failure to increase size (J:132538)

hematopoietic system

decreased B cell number ( J:76134 )

• peripheral B cells are reduced compared to in Tg(IghelMD4)4Ccg mice

decreased marginal zone B cell number ( J:132538 )

• very few B cells in the spleen have surface markers indicative of the marginal zone phenotype

abnormal spleen primary B follicle morphology ( J:76134 )

• the number of B follicles is decreased compared to in Tg(IghelMD4)4Ccg mice

abnormal B cell physiology ( J:76134 )

• surface levels of IgMa are decreased 7- to 11-fold compared to in Tg(IghelMD4)4Ccg mice

Genotype
MGI:3799690

cx8

• Allelic Composition: Tg(ML5sHEL)5Ccg/0; Tg(TcrHEL3A9)1Mmd/0
• Genetic Background: involves: C57BL/6 * C57BL/10 * C57BR/cd

immune system

decreased double-positive T cell number ( J:78309 )

• there is a 32-fold reduction in the number of double positive T cells in the thymus

abnormal CD4-positive, alpha beta T cell morphology ( J:78309 )

• there is reduced surface expression of T cell receptor components compared to mice transgenic for just the TCR transgene

• T cells also express surface markers indicative of recently being activated (high CD44, low CD45RB)

decreased CD4-positive, alpha-beta T cell number ( J:78309 )

• CD 4 T cell numbers in the lymph nodes are reduced by almost three-quarters

• the number of lymph node CD4 T cells bearing a transgenic TCR is reduced 2- to 4- fold compared to mice transgenic just for the TCR

abnormal CD4-positive, alpha-beta T cell physiology ( J:78309 )

• CD4 T cells have a greatly reduced capability to activate and help B cell antibody production in vivo

abnormal T cell activation ( J:78309 )

• vitro TCR stimulation leads to greatly reduced expression of CD69 compared to T cells from mice transgenic for just the TCR

abnormal T cell proliferation ( J:78309 )

• CD4 T cells do not proliferate to hen egg lysozyme antigen compared to CD4 T cells from mice carrying just the TCR transgene

hematopoietic system

decreased double-positive T cell number ( J:78309 )

• there is a 32-fold reduction in the number of double positive T cells in the thymus

abnormal CD4-positive, alpha beta T cell morphology ( J:78309 )

• there is reduced surface expression of T cell receptor components compared to mice transgenic for just the TCR transgene

• T cells also express surface markers indicative of recently being activated (high CD44, low CD45RB)

decreased CD4-positive, alpha-beta T cell number ( J:78309 )

• CD 4 T cell numbers in the lymph nodes are reduced by almost three-quarters

• the number of lymph node CD4 T cells bearing a transgenic TCR is reduced 2- to 4- fold compared to mice transgenic just for the TCR

abnormal CD4-positive, alpha-beta T cell physiology ( J:78309 )

• CD4 T cells have a greatly reduced capability to activate and help B cell antibody production in vivo

abnormal T cell activation ( J:78309 )

• vitro TCR stimulation leads to greatly reduced expression of CD69 compared to T cells from mice transgenic for just the TCR

abnormal T cell proliferation ( J:78309 )

• CD4 T cells do not proliferate to hen egg lysozyme antigen compared to CD4 T cells from mice carrying just the TCR transgene

cellular

abnormal T cell proliferation ( J:78309 )

• CD4 T cells do not proliferate to hen egg lysozyme antigen compared to CD4 T cells from mice carrying just the TCR transgene

Genotype
MGI:3800476

cx9

• Allelic Composition: Igh^tm1Rbr/Igh⁺; Tg(IgkHyHEL10)1Rbr/0; Tg(ML5sHEL)5Ccg/0
• Genetic Background: involves: C57BL/6 * C57BL/6JSfd

hematopoietic system

abnormal B cell morphology ( J:132538 )

• there is a 2-fold reduction in the number of HEL-specific B cells found in the spleen

increased immature B cell number ( J:132538 )

• HEL-specific B cells in the spleen have mostly have an immature phenotype

decreased follicular B cell number ( J:132538 )

• few HEL-specific B cells in the spleen are found in the follicular region or have surface markers indicative of follicular B cells

decreased marginal zone B cell number ( J:132538 )

• very few HEL-specific B cells in the spleen are found in the marginal zone or have surface markers indicative of the marginal zone phenotype

immune system

abnormal B cell morphology ( J:132538 )

• there is a 2-fold reduction in the number of HEL-specific B cells found in the spleen

increased immature B cell number ( J:132538 )

• HEL-specific B cells in the spleen have mostly have an immature phenotype

decreased follicular B cell number ( J:132538 )

• few HEL-specific B cells in the spleen are found in the follicular region or have surface markers indicative of follicular B cells

decreased marginal zone B cell number ( J:132538 )

• very few HEL-specific B cells in the spleen are found in the marginal zone or have surface markers indicative of the marginal zone phenotype

abnormal B cell anergy ( J:132538 )

• B cells are anergic when stimulated with HEL antigen as determined by reduced antibody production, no upregulation of activation markers CD69 and CD86, and failure to increase size

• these anergic B cells have a short half-life of less than three days

• however, these anergic B cells can proliferate in response to BCR-independent activation

Genotype
MGI:3799695

cx10

• Allelic Composition: Tg(ML5sHEL)5Ccg/0; Tg(TcrHEL3A9)1Mmd/0; Tg(TLK2mHEL)2Ccg/0
• Genetic Background: involves: C57BL/6JSfd * C57BL/10 * C57BR/cd

hematopoietic system

decreased double-positive T cell number ( J:78309 )

• there is a 32-fold reduction in the number of double positive T cells in the thymus

abnormal CD4-positive, alpha beta T cell morphology ( J:78309 )

• there is reduced surface expression of T cell receptor components compared to mice transgenic for just the TCR transgene

• T cells also express surface markers indicative of recently being activated (high CD44, low CD45RB)

decreased CD4-positive, alpha-beta T cell number ( J:78309 )

• CD 4 T cell numbers in the lymph nodes are reduced by almost three-quarters

• the number of lymph node CD4 T cells bearing a transgenic TCR is reduced 2- to 4- fold compared to mice transgenic just for the TCR

abnormal CD4-positive, alpha-beta T cell physiology ( J:78309 )

• CD4 T cells have a greatly reduced capability to activate and help B cell antibody production in vivo

abnormal T cell activation ( J:78309 )

• in vitro TCR stimulation leads to greatly reduced expression of CD69 compared to T cells from mice transgenic for just the TCR

abnormal T cell proliferation ( J:78309 )

• CD4 T cells do not proliferate to hen egg lysozyme antigen compared to CD4 T cells from mice carrying just the TCR transgene

immune system

thyroid gland inflammation ( J:78309 )

• spontaneous thyroiditis does not occur in these mice as it does in mice doubly transgenic for Tg(ML5sHEL)5Ccg and Tg(TcrHEL3A9)1Mmd transgene

decreased double-positive T cell number ( J:78309 )

• there is a 32-fold reduction in the number of double positive T cells in the thymus

abnormal CD4-positive, alpha beta T cell morphology ( J:78309 )

• there is reduced surface expression of T cell receptor components compared to mice transgenic for just the TCR transgene

• T cells also express surface markers indicative of recently being activated (high CD44, low CD45RB)

decreased CD4-positive, alpha-beta T cell number ( J:78309 )

• CD 4 T cell numbers in the lymph nodes are reduced by almost three-quarters

• the number of lymph node CD4 T cells bearing a transgenic TCR is reduced 2- to 4- fold compared to mice transgenic just for the TCR

abnormal CD4-positive, alpha-beta T cell physiology ( J:78309 )

• CD4 T cells have a greatly reduced capability to activate and help B cell antibody production in vivo

abnormal T cell activation ( J:78309 )

• in vitro TCR stimulation leads to greatly reduced expression of CD69 compared to T cells from mice transgenic for just the TCR

abnormal T cell proliferation ( J:78309 )

• CD4 T cells do not proliferate to hen egg lysozyme antigen compared to CD4 T cells from mice carrying just the TCR transgene

endocrine/exocrine glands

thyroid gland inflammation ( J:78309 )

• spontaneous thyroiditis does not occur in these mice as it does in mice doubly transgenic for Tg(ML5sHEL)5Ccg and Tg(TcrHEL3A9)1Mmd transgene

cellular

abnormal T cell proliferation ( J:78309 )

• CD4 T cells do not proliferate to hen egg lysozyme antigen compared to CD4 T cells from mice carrying just the TCR transgene

Genotype
MGI:3793444

cx11

• Allelic Composition: Tg(IghelMD4)4Ccg/0; Tg(ML5sHEL)5Ccg/0
• Genetic Background: NOD.B6-Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg/Dvs

immune system

abnormal B cell morphology ( J:89156 )

• there is no decrease in the number of B cells expressing the transgenic antibody compared to singly transgenic NOD mice that carry just the antibody transgene

• this suggests defect in the NOD strain of deleting B cells that recognize soluble self antigens

abnormal B cell clonal deletion ( J:89156 )

• Background Sensitivity: the normal number of B cells found in these mice demonstrate a defect in the NOD strain of deleting B cells that recognize soluble self antigens

decreased IgM level ( J:89156 )

• very little IgM is detectable in the sera despite the presence of soluble antigen for the transgenic antibody

abnormal B cell anergy ( J:89156 )

• B cells expressing the transgenic antibody are anergic as determined by the lack of HEL specific antibody found in the sera

• anergy occurs both centrally (i.e. in the bone marrow) and in the periphery

• this anergy can be reversed by stimulating B cells in vitro

• when compared to singly transgenic controls, antibody production following BCR and CD40 stimulation is less suppressed in doubly transgenic NOD mice than in doubly transgenic C57BL/6 mice (2.6-fold less vs 4.5 fold less)

hematopoietic system

abnormal B cell morphology ( J:89156 )

• there is no decrease in the number of B cells expressing the transgenic antibody compared to singly transgenic NOD mice that carry just the antibody transgene

• this suggests defect in the NOD strain of deleting B cells that recognize soluble self antigens

abnormal B cell clonal deletion ( J:89156 )

• Background Sensitivity: the normal number of B cells found in these mice demonstrate a defect in the NOD strain of deleting B cells that recognize soluble self antigens

decreased IgM level ( J:89156 )

• very little IgM is detectable in the sera despite the presence of soluble antigen for the transgenic antibody

Genotype
MGI:3800597

tg12

• Allelic Composition: Tg(ML5sHEL)5Ccg/0
• Genetic Background: C57BL/6-Tg(ML5sHEL)5Ccg

immune system

abnormal B cell anergy ( J:78308 )

• abnormally low levels of anti-hen egg lysozyme (HEL) antibodies are made in response to immunization with HEL

• 50-fold lower levels of anti-HEL antibodies occur in response to immunization with HEL coupled with sheep red blood cells, which is a T cell-independent method of activating B cells

homeostasis/metabolism

abnormal circulating protein level ( J:78308 )

• hen egg lysozyme (HEL) is found in circulation at a median level of 17.3 ng ml^-1

Genotype
MGI:3800598

tg13

• Allelic Composition: Tg(ML5sHEL)5Ccg/0
• Genetic Background: involves: C57BL/6JSfd * CBA

immune system

abnormal B cell anergy ( J:78308 )

• abnormally low levels of anti-hen egg lysozyme (HEL) antibodies are made in response to immunization with HEL

abnormal T cell anergy ( J:78308 )

• T cell response to HEL antigen in vitro is much lower than T cells from non-transgenic controls